AKT1 and cancer: We have observed that selective inhibition of Src family tyrosine kinases can re-sensitize Rac-driven BRAFi-resistant cells to BRAF inhibitors [14, 15, 39] and Supplementary Fig. S5D; however, selective Src kinase inhibitors are not currently being pursued clinically as anti-cancer therapies.